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Adoptive transfer of T cells transgenic for tumor-reactive T-cell receptors (TCR) is an
attractive immunotherapeutic approach. However, clinical translation is so far limited
due to challenges in the identification of suitable target antigens as well as TCRs
that are concurrent safe and efficient. Definition of key characteristics relevant for
effective and specific tumor rejection is essential to improve current TCR-based adoptive
T-cell immunotherapies. We here characterized in-depth two TCRs derived from the
human leukocyte antigen (HLA)-mismatched allogeneic repertoire targeting two different
myeloperoxidase (MPO)-derived peptides presented by the same HLA-restriction
element side by side comprising state of the art biochemical and cellular in vitro, in vivo,
and in silico experiments. In vitro experiments reveal comparable functional avidities,
off-rates, and cytotoxic activities for both TCRs. However, we observed differences
especially with respect to cytokine secretion and cross-reactivity as well as in vivo
activity. Biochemical and in silico analyses demonstrate different binding qualities of
MPO-peptides to the HLA-complex determining TCR qualities. We conclude from our
biochemical and in silico analyses of peptide-HLA-binding that rigid and high-affinity
binding of peptides is one of the most important factors for isolation of TCRs with high
specificity and tumor rejection capacity from the MHC-mismatched repertoire. Based on
our results, we developed a workflow for selection of such TCRs with high potency and
safety profile suitable for clinical translation.
Keywords: T-cell receptor (TCR), peptide-MHC modeling (p-MHC modeling), adoptive T-cell transfer therapy,
TCR cell therapy, TCR identification, TCR characterization, trimolecular complex (TCR-p-MHC), target antigen
characterization
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INTRODUCTION
Adoptive T-cell transfer of immune receptor transgenic T cells
has demonstrated high clinical potential especially for chimeric
antigen receptors (CAR) (1). TCRs, however, are far behindCARs
with respect to clinical translation. A number of candidate TCRs
have been proposed (2–4), however, only a few clinical trials
have been published (5, 6) likely explainable by the challenging
selection process for suitable peptide antigens as well as equally
potent and safe TCRs.
Diverse qualities of TCRs have been described to be essential
and potentially predict anti-tumor reactivity in vivo as especially
functional avidity and affinity of TCRs (7–11). In addition, slow
dissociation half-life of TCRs from peptide-MHC complexes (p-
MHC) has been reported to correspond with in vivo activity (12).
There are less recommendations for high avidity TCRs deriving
from the allogeneic or xenogeneic environment or selected by
affinity maturation. This is especially important as these TCR
may harbor an enhanced risk profile for crossreactivity and
therefore toxicity (13, 14). Furthermore, the functionality and
efficiency of transferred TCR cell-surface expression depend
on the intrinsic quality of the TCR complex (15) and the T-
cell specificity might be affected by the formation of mixed
heterodimers composed of endogenous and transgenic TCR
chains (16).
Suitable target epitope selection remains equally difficult
despite the large number of possible human leukocyte antigen
(HLA)-peptide ligands. Peptide-HLA binding affinity has been
identified as particular important (17, 18). Candidate epitopes are
often selected by prediction algorithms. Sequence- and stability-
based p-MHC binding predictions are valuable tools (19, 20)
to get approximated binding qualities (21) and are used for
initial peptide-candidate screenings (22). In addition, combined
approaches using sequence- and structure-based algorithms have
been applied (23, 24). Peptide ligands to be used as target antigens
in cancer can be also directly identified by immunopeptidomics
(25, 26) to be potentially used in combination with in-silico
p-MHC binding prediction (26, 27).
Defining priorities for the selection of epitope and TCR
candidates, including the non-self-repertoire, would be an
important step to foster clinical translation. We here present an
in-depth characterization and comparison of two TCRs identified
in a single HLA-mismatched allorestricted approach (sHLAm)
recognizing two different peptides derived frommyeloperoxidase
(MPO) sharing the same restriction element HLA-B∗07:02
(HLA-B7). One of the TCRs has been previously described
as highly specific and tumor-reactive (27, 28). Identification
and characterization of the second TCR are described in this
manuscript. State of the art key experiments investigating
functional qualities of TCR-transgenic TCR as well as in-depth
target peptide characterization have been applied to address
Abbreviations: B2M, beta-2-microglobulin; EC50, half maximal effective
concentration; IVT, in vitro transcribed; koff-rate, dissociation half-live of TCR
from p-MHC complex; MD simulation, molecular dynamics simulation; MFI,
mean fluorescence intensity; RMSD, root mean square deviation; RMSF, root
mean square fluctuations; sHLAm, single HLA-mismatched approach; TCM, T
cells enriched for the central memory phenotype; TCRm, mouse TCR-β chain.
the question, which set of in vitro and in silico analyses may
support straight forward selection of promising peptide and TCR
candidates suitable for clinical translation.
MATERIALS AND METHODS
Cell Lines and T Cells
The isolation of peripheral blood mononuclear cells (PBMC),
the isolation of naïve CD8+ T cells and the culturing of target
cell lines were realized as described previously (27, 28). For
analyses of the MPO-specific TCRs the following cell lines were
used: NB-4 (Cell Lines Service, CLS, Germany), SiG-M5 (DSMZ),
K562 (ATCC CCL-243), KG1a (CLS), HL-60 (CLS), ML2 (The
CABRI consortium), C1R (26), NSO-IL15 (kindly provided by
S.R. Riddell), 293Vec-RD114 (BioVec Pharma), and variant types
of lymphoblastoid cell lines (LCL) (kindly provided by Steve
Marsh). Cell culturing was done as previously described (27). All
cell lines were periodically tested for mycoplasma negative status
by PCR and cell line authentication was done by flow cytometry-
based analyses of cell surface markers and HLA-A∗- and HLA-
B∗ typing by next-generation sequencing (Center for Human
Genetics and Laboratory Diagnostics, Munich, Germany).
Antibodies and HLA Multimers
Antibodies used for activation of T cells and flow cytometry:
anti-hCD3 FITC [UCHT1; Becton Dickinson, Franklin Lakes,
NJ, USA (BD)], anti-hCD4 APC/Pacific Blue (RPA-T4; BD),
anti-hCD8 APC/V450 (RPA-T8; BD), anti-hCD62L PE, anti-
hCD45RO PE (UCHL1; BD), anti-hCD45RA APC (HI100; BD),
anti-mouse TCR-β chain (anti-TCRm) FITC/PE/APC (H57-597,
BD), anti-hCD45 APC [J.33; Beckman Coulter (BC)], anti-hCD3
AF700 (UCHT1; BD), anti-hCD5 PECyTM5 (UCHT2; BD), anti-
hCD4 V450 (RPA-T4; BD), anti-HLA-B7 PE (BB7.1; Merck).
HLA multimers were synthesized as previously described (29).
Selection and Expansion of T Cells
Specific for the MPO Ligands
Expansion of T cells specific for the HLA-B7 MPO2-ligand was
performed as described previously (27). T cells were subsequently
screened for functionality. Prior to the multimer sort, expanded
T cells from the MPO2 single HLA-mismatch setting were
co-incubated with lethally irradiated (30Gy) C1R-B7 tumor
cells to remove unspecific HLA-B7-alloreactive T cells (30).
After 12 h of co-incubation, the T cells were stained with
an anti-human CD137-APC antibody and depleted by MACS
sorting (Miltenyi) according to the manufacturer instructions.
Subsequently, peptide-specific T cells were sorted using HLA
multimers on a flow cytometric cell sorter (MoFlo; Dako,
Glostrup, Denmark). HLA-multimer positive T cells were cloned
by limited dilution.
TCR Isolation and Retroviral TCR Transfer
The usage of TCR variable alpha and beta domains were
determined by PCR followed by Sanger Sequencing as described
previously (31). After in silico murinization and cysteine
modification of the constant domains of the TCR and insertion
of an additional cysteine bridge, the complete sequence was
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codon-optimized (Genscript, Piscataway Township, NJ, USA)
and cloned by a bi-cistronic construct, consisting of both
TCR chains into the pMP71 backbone. To produce retroviral
supernatants, the embryonal kidney cell line 293Vec-RD114
(BioVec Pharma, Québec, Canada) was used and a retroviral
transduction protocol for TCR- and HLA-allele transduction as
described previously (32).
HLA-Vector Constructs Used for T-Cell
Clone Isolation, Testing of Specificity, and
HLA-Peptide Restriction
The different tumor cell lines without endogenous gene
expression of MPO or the desired restriction element HLA-A1,
HLA-A2, HLA-B7, HLA-B15, or HLA-B44, respectively, were
transduced with the retroviral vector pMP71 containing the
HLA of interest attached to green fluorescent protein (GFP) or
MPO attached to Discosoma Red Fluorescent Protein (DsRed)
Express II. The sequences were cloned into the vector as a
bi-cistronic construct separated by the porcine teschovirus-1-
derived peptide element P2A. For the generation of in vitro
transcribed (IVT) mRNA the bi-cistronic constructs were cloned
into the plasmid pcDNA3.1(–) (Thermo Fisher Scientific). HLA-
allele retroviral transduced cell lines are indicated with the
appendix e.g., “-B7”.
MPO, MPO2, and MPO5 Mini-Gene Design
and Expression in Target Cell Lines
Gene fragments containing the MPO2 or MPO5 sequence in
the center were amplified by designing primers resulting in
oligonucleotides of an overall length of ∼200 base pairs flanked
by a start and a stop codon. The following primers were used




TAGTCGACGTACTTCCTCATGGCCGTTG3′ using the MPO
gene derived from NB-4 cells as template. For the expression
of mini-genes in HLA-B∗07:02-positive target cells, amplified
oligonucleotides were cloned into the retroviral vector MP71
containing also dsRed Express II as selection marker. Retroviral
supernatant production and retroviral transduction was done as
previously described (32).
Functional Characterization of T-Cell
Clones and TCR-Transgenic T Cells
The cytotoxic reactivity of T cells was tested by flow cytometry
making use of changes in signal of the HLA-B7eGFP-transgenic
target cells during co-cultivation for different time periods
and effector to target ratios. For relative quantification of
cytotoxicity, AccuCheck counting beads were used according to
the manufacturer’s protocol (Thermo Fisher Scientific) and the
results were normalized to either non-TCR-transduced T cells or
irrelevant T-cell clones. The supernatants of the co-cultivation
were used to measure IFN-γ by ELISA (BD) or GM-CSF,
IFN-γ, and lL-2 multiplexed by flow cytometry (Miltenyi Biotec)
according to the manufacturer’s instructions. The functional
avidity of the different TCR was assessed as previously described
(27). The 58 HLA-B7 restricted ligands used for the analysis
of potential off-target reactivity of TCRF5.4 as tested in co-
cultivation experiments, were synthesized (EPS221 synthesizer,
Abimed, Langenfeld, Germany) following the 9-fluorenylmethyl-
oxycarbonyl/tertbutyl (Fmoc/tBu) methodology. To define
peptide residues essential for the recognition by TCRF5.4, amino
acid substitution assays using alanine- and threonine variants
of the MPO2 peptide (Genscript) were performed as described
previously (32). Based on the acquired motif, the ScanProsite
tool (SIB Swiss Institute of Bioinformatics) was used to identify
proteins containing the same pattern. If not stated otherwise, the
effector to target ratio was set to 1:1 for the co-incubation assays
using 20,000 cells in each fraction.
UV-Mediated Peptide Exchange
Biotinylated HLA-B7 monomers loaded with the UV-cleavable
epitope AARG(J)TLAM were created as previously described
(33). Peptide-HLA stability was measured using the protocol on
the basis of Rodenko et al. (34). In brief, HLA-B7 monomers
loaded with the UV-sensitive peptide were exposed to UV light
(366 nm) in the presence of graded amounts (0–200µM) of
MPO peptides. Afterward 1:10 dilutions of the UV-exchanged
monomers were adhered via streptavidin to the bottom of a 96-
well plate (F96 maxisorp nunc-immune plate, Thermo scientific)
and a beta-2-microglobulin ELISA was performed. The OD
measurements were performed on a Tecan Sunrise multi-well-
reader using Magellan software (version 7.2).
Flow Cytometry-Based koff-Rate
Determination of TCRF5.4 and TCR2.5D6
The koff-rate was analyzed as described previously (35). In
brief, 5 × 106 TCR-transduced T cells were stained with the
reversible TCR-specific multimer for 45min and subsequently
incubated with an anti-human CD8 eF450 antibody (Thermo
Fisher Scientific) for 20min. Washed T cells were then stained
with 0.2mg propidium iodide solution for 5min. 100 µl of
the stained TCR-transduced suspension (1–10 × 106 cell/ml)
was added to 900 µl FACS buffer prepared in a koff-rate FACS
tube under constant cool condition (qutools GmbH, Munich,
Germany) for the whole measurement. After initiation of analysis
in a CyAn ADP Lx 9 color flow cytometer (Beckman Coulter,
Miami, US) for 30 s, 1ml 2mM D-biotin was injected into
the koff-rate FACS tube. The measurement was stopped after
recording events for a total of 15min. Data were analyzed using
FlowJo v9.5.2 software (FlowJo, LLC, Ashland) and a one-phase
exponential decay curve fitting tool of GraphPad Prism (version
7.04, San Diego, USA).
Human AML Tumor Models and Adoptive
T Cell Transfer
The immunocompromised NSG (NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ) mouse strain was used to establish an NB4
derived myeloid sarcoma model following the experimental
procedure as described previously (28). In brief, 1 × 107 NB4-
B7eGFP- or NB4-B15eGFP tumor cells were subcutaneously
inoculated into the right or left flank, respectively. One day prior
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to intravenous injection of 2 × 107 TCR-transgenic CD8+ TCM
(day 8), mice were irradiated with 1Gy total body irradiation.
Irradiated (80Gy) human interleukin-15 producing murine
NSO cells were injected intraperitoneally twice per week (27).
The mice were maintained according to conventional institute
guidelines and with the approval of local authorities.
Molecular Modeling
MPO5- and the respective variant-HLA-B7 complexes were
simulated based on the crystal structure of the HLA-B7 complex
bound to the peptide TPQDLNTML (Protein Data Bank (PDB)
ID: 4U1H) (36) as template. The MPO2- and MPO2 variant-
HLA-B7 complexes were modeled as follows: the MPO5-HLA-B7
protein conformations were directlymodeled based on 4U1H; for
the backbone conformation of the MPO2 peptide and its variants
the crystal structure of the octamer HLA-B∗08:01 complex bound
to the peptide GGKKKYKL (PDB ID: 1AGD) (37) was taken as
no experimental structure of an octamer-HLA-B7 complex was
available. For this the HLA α1 and α2 subdomains of 4U1H and
1AGD were structurally aligned using PyMOL, version 1.5.0.4
(Schrödinger). Only the subdomains α1 and α2 of the HLA-B7
protein were considered for modeling. Mutations of the peptide
sequences and conformational adaption of the highly flexible
binding site residues E70 or R62 were conducted with IRECS
(38, 39). Molecular dynamics (MD) simulations and system setup
as well as MD analysis were performed with AmberTools16
and the Amber16 software package (40). The Amber ff14SB
potential energy function and parameter set (41) were chosen
to model the solute. The modeled complexes were simulated in
a neutralized (Na+, Cl−), rectangular box of water molecules
[TIP3P force field (42)] with a minimum solute distance of 14
Å to the box boundary. MD simulations were performed with
the CUDA compatible GPU version of pmemd, applying periodic
boundary conditions (43). Long-range electrostatic interactions
were computed with the Particle Mesh Ewald (PME) method
(43). A cutoff of 12 Å was used for the computation of non-
bonded interactions. MD simulations were performed with a
time step of 1 fs. The SHAKE algorithm (44) was applied to
constrain bonds involving hydrogen atoms. Temperature and
pressure were controlled applying the Berendsen thermostat and
barostat (45), using coupling time constants of 0.5 ps (heat up)
and 10.0 ps (simulations at 300K), respectively, and a pressure
relaxation time of 2.0 ps. Systems were heated up to room
temperature in the NVT ensemble with a sequence of heat up
MD simulations at stepwise increasing temperatures totaling up
to 1.5 ns (0 K: 10 ps; 5 K, 10K, 20K, 50 K: 50 ps; 100K, 200K, 200
K: 100 ps; 200K, 300 K: 200 ps; 300 K: 590 ps), using different
restraint settings (0 K, 5 K, 10K, 20 K: 2.39 kcal mol−1 Å−2 for
all solute atoms; 50K, 100K, 200 K: 2.39 kcal mol−1 Å−2 for
all backbone heavy atoms; 200 K: 0.24 kcal mol−1 Å−2 for all
backbone heavy atoms; 200K, 300 K: 0.24 kcal mol−1 Å−2 for
all backbone heavy atoms of the HLA-B7 protein; 300 K: no
restraints). The heated systems were equilibrated in the NPT
ensemble for 1.5 ns at 300K and 1 bar. All systems were simulated
for 450 ns in total by performing three independent 150 ns MD
simulations per system. Trajectory processing and analysis was
performed with cpptraj (46). For the latter, MD frames were
extracted from the three trajectories every 100 ps and clustered
with respect to their conformation, using the average-linkage
hierarchical agglomerative clustering approach (47), applying a
minimum cluster distance of 0.75 Å and the best-fit coordinate
RMSD of the peptide backbone heavy atoms as distance
metric. Hydrogen bonds were calculated applying default settings
of cpptraj. Peptide-HLA-B7 protein binding affinities were
estimated applying the Molecular Mechanics/Generalized Born
Surface Area (MM/GBSA) approach (48, 49) with the single
trajectory protocol as implemented in MMPBSA.py (50) using
default settings [GB model: OBC-II model (51), atomic radii:
mbondi2 (51), no contributions from solvated ions, surface
tension applied to the solvent-accessible surface area: 0.0072
kcal mol−1 Å−2 (52)]. Solute entropy contributions were
neglected in the binding affinity estimates. For MM/GBSA free
energy computations, snapshots from all three MD replica were
combined, discarding the snapshots from the first 25 ns of
each MD replicon. For the calculation of root mean square
fluctuations (RMSF), each 150 ns-long MD replicon was split
in six 25 ns bins and Cα-RMSFs were calculated for each bin
separately with cpptraj. To yield the final RMSF values for each
MD replicon, the single RMSF values of each bin were averaged.
Electrostatic potentials were calculated using the PDB2PQR
server (Version 2.0.0) and APBS (Version 1.3) (53, 54), keeping
default settings. Figures of peptide-HLA-B7 complexes were
generated with VMD (Version 1.9.2) (55).
Statistics
Statistical analyses of T-cell experiments were performed using
GraphPad Prism software version 7.04. Results are presented as
standard deviations (SD) of the mean. Samples were compared
using the non-parametric Mann-Whitney’s t-test and multiple
t-test as indicated in the figure legends.
RESULTS
Identification of a Novel HLA-B7
Allorestricted TCR Targeting a New
MPO-Derived Epitope
We have previously identified a leukemia-associated HLA-
B0702-restricted epitope derived from MPO (MPO466−474
named MPO5) by mass spectrometry (MS) as well as the
TCR2.5D6 derived from the sHLAm T-cell repertoire with high
peptide specificity and leukemic reactivity suitable for clinical
application in the context of allogeneic stem cell transplantation
(27). In our MS-based approach additional MPO epitopes
presented on myeloid tumor cells have been identified (27)
and selected for stimulation in sHLAm approaches to identify
new MPO-specific TCRs. In fact, one novel TCR candidate
(TCRF5.4) directed against the MPO145−152-peptide (MPO2,
Table 1) with promising characteristics in early screening
analyses was discovered. Shortly summarized, this TCR was
identified after prior CD137 depletion of alloreactive T cells
as previously described (30) followed by MPO2-multimer
sorting and T-cell cloning (Supplementary Figures 1A,B).
Specific T-cell clones were detected (Supplementary Figure 1C)
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TABLE 1 | Characteristics of analyzed p-MHC complexes.











Alias Peptide Source Sequence Affinity (nM) Score Stability (hrs) V50 (log10 M)* V50 (
◦C) Half-life (hrs) 37◦C
MPO5 MPO466 (27) NPRWDGERL 36.75 23 2.69 −5.535 46.4 4.1
MPO2 MPO145 (27) TPAQLNVL 305.31 n.a. 4.01 −4.671 46.3 3.5
MPO2+L1 MPO144 LTPAQLNVL 15292.21 12 0.35 −3.728 44.0 2.9
pp65 417-426 (58) TPRVTGGGAM 3.86 19 6.04 n.a. 50.0 5.6
*pooled values of at least three independent experiments, n.a., not available.
expressing all the same TCR chains (Vα2 and Vβ1, TCRF5.4).
CD8+ central memory T cells (TCM) transduced with an
optimized and cysteine-modified TCRF5.4 construct (59, 60)
displayed high transduction efficacy and TCR expression
(Supplementary Figure 1D). TCRF5.4-transduced CD8+
TCM were highly specific for target cells either pulsed with
or endogenously presenting the respective peptide after mini-
gene transfer (Supplementary Figure 1E). Moreover, primary
malignant cells derived from patients with myeloproliferative
neoplasia (MPN) expressing MPO and HLA-B7 were well
recognized (Supplementary Figure 1F). To exclude major
cross-reactivity, we screened common HLA alleles expressed
on different lymphoblastoid cell lines (LCL) pulsed with
MPO2 and compared the reactivity to non-pulsed conditions
(Supplementary Figure 1G; Supplementary Table 1). TCRF5.4-
transgenic T cells showed alloreactivity against LCL8 carrying
the HLA-alleles A∗02:04/B∗51:01. Co-incubation of TCRF5.4-
transgenic T cells with C1R-A2 or Tapasin-1 deficient T2
(HLA-A2+/HLA-B51+) confirmed MPO2-independent
HLA-B51 cross-reactivity (Supplementary Figure 1H;
Supplementary Table 1). However, no recognition of TCRF5.4-
transgenic T cells was seen against a set of 58 HLA-B7 restricted
peptides (Supplementary Figure 1I). The TCRF5.4 peptide
crossreactivity risk was tested on HLA-B7+ LCL1 cells by
using alanine or threonine substitution variants (Ala/Thr-scan)
of MPO2 (Supplementary Figures 1J,K). Interestingly, we
observed different TCR-binding motifs for both amino acids
substitution variants indicating a flexible binding pattern of the
TCR toward the p-MHC. Applying the ScanProsite tool (61) for
the combined Ala/Thr-scan motif (X-P-A-Q-X-X-V-X) revealed
297 hits outside the MPO source protein whereas only 1 hit was
found if the motifs were analyzed separately.
Differences in Transgenic TCR Expression
Between TCRF5.4 and TCR2.5D6 as Well
as Quantitative and Qualitative Cytokine
Secretion in vitro
Based on the qualities of TCRF5.4, the same source protein of
recognized peptides and the same restriction element, we decided
to compare this TCR to the recently characterized TCR2.5D6 to
investigate which TCRmay be superior and to define prospective
criteria for rapid selection of most suitable allorestricted TCRs for
adoptive transfer of TCR-transgenic T cells.
The TCR-transduction rates of recipient T cells differed
in most but not all experiments approximately by 10% as
the mean was 72.2% for TCRF5.4 and 82.3% for TCR2.5D6
(Figure 1A, left). The mean fluorescence intensity (MFI) of
TCRF5.4 expression was also in many experiments inferior
compared to TCR2.5D6 (Figure 1A, right). We observed that
TCR2.5D6 is more efficiently expressed as nearly all positive
TCR-signal is located on the surface of the T cells whereas
TCRF5.4 is not fully expressed (Figure 1B).
Subsequently we investigated the functional avidity of both
TCRs toward p-MHC complexes on MPO-negative, HLA-B7-
transgenic KG-1a cells. No significant difference in EC50 values
was observed between both TCR-transduced T cells (Figure 1C,
left). The colored data points in Figures 1A,C symbolize the
same pairs of transgenic T cells of different TCR-transductions
used for the measurements. Our data show that the EC50 values
were comparable for both TCR independent of the differences
in TCR expression. Similarly, koff-rate experiments analyzing the
dissociation time of both TCRs from the p-MHC complex were
also comparable for both TCR (Figure 1D). Thus, functional
avidity and koff-rate analyses revealed similar results despite
differences of TCR-expression and surface density levels.
For the following characterization of both TCRs in co-
incubation assays, we used MPO high expressing AML cell
lines HL60, ML2, and NB4 (transgenic for HLA-B7) and
SiG-M5 (endogenous HLA-B7 expression). HLA-B7 surface
expression analysis revealed different levels of HLA-B7 within
these cell lines (Figure 1E). First, we used the AML cell lines
to investigate an extended cytokine profile of TCRF5.4- and
TCR2.5D6-transduced PBMCs. Here we observed differences
in the quantity but also quality of cytokine secretion between
both TCRs (Figure 1F). The results, representatively shown
for NB4, demonstrate increased amounts of IFN-γ, GM-
CSF, and IL-2 for TCR2.5D6-transduced PBMCs as well as
significantly enhanced secretion of IL-10, IL-17A, and TNFα
compared to PBMCs transduced with TCRF5.4. Focusing
on CD8+ T cells in subsequent assays, all four tumor
cell lines with endogenous MPO expression were recognized
consistently by TCRF5.4- and TCR2.5D6-transduced T cells,
respectively (Figure 1G). Thereby, TCRF5.4-transduced CD8+ T
cells released substantially lower amounts of IFN-γ, GM-CSF,
Frontiers in Immunology | www.frontiersin.org 5 June 2019 | Volume 10 | Article 1485
Audehm et al. Allogeneic TCR for Adoptive Transfer
FIGURE 1 | TCR surface expression and quality of cytokine release differs between TCRF5.4- and TCR2.5D6-transduced T cells. (A) Transduction efficiency
measured by flow cytometry analysis of surface expression (left) and MFI (right) of TCRF5.4 (green) and TCR2.5D6 (blue). Connections between data points symbolize
couples of the same recipient T cells used for TCR transduction (n = 11). Colored and bigger data points represent pairs of T cells that were also used for the
functional avidity analyzes in (C). (B) Surface and intracellular anti-TCRm staining of both TCR (X-axis: surface TCRm signal, Y-axis: intracellular TCRm signal)
measured by flow cytometry (n = 2). (C) Functional avidity of TCRF5.4- or TCR2.5D6-transduced PBMC analyzed in response to KG1a-B7 pulsed with graded
amounts of MPO2 or MPO5 at an E/T ratio of 1:1 after 20 h of co-incubation. Half-maximal IFN-γ release was calculated using logarithmic dose-response fitting
algorithm with variable slope (EC50) of GraphPad Prism. Mean ± SD of triplicates of one representative experiment are shown (n = 6). Colored data pairs represent T
cell pairs also used in (A). (D) Flow cytometry based koff-rate measurements of TCRF5.4 (n = 4) and TCR2.5D6 (n = 5). The dissociation half-lives calculated by
one-phase decay algorithm using GraphPad Prism are shown for both TCR. (E) MFI of HLA-B7 expression of selected AML cell lines measured by flow cytometry. (F)
Multi-cytokine release of TCRF5.4 or TCR2.5D6 transduced PBMC in response to the HLA-B7-transgenic AML cell line NB4. NB4 is representatively shown for all 4
tested AML cell lines HL60, ML2, and SiG-M5. Standard deviations of the mean of triplicates are shown (n = 2 for each cell line) (G) IFN-γ secretion by TCRF5.4 or
TCR2.5D6 transduced CD8+ TCM in response to AML-cell lines with endogenous MPO expression measured by ELISA. 10.000 effector cells were used in a ratio of
1:1. Standard deviations of the mean of triplicates are shown (n = 4). (Gi−iv) Cytokine secretion (GM-CSF, IFN-γ, and IL-2) measured by flow cytometry based
multiplex analysis in response to selected AML cell lines is shown in triplicates either unpulsed or additionally pulsed with MPO2 or MPO5. (H) IFN-γ release (left
panels) and cytotoxicity (right panels) of TCRF5.4- or TCR2.5D6-transduced CD8+ TCM against NB4-B7 cells analyzed for E/T titrations ranging from 5:1 to 0.0031:1
using a constant target cell amount of 20.000 for different periods of co-cultivation (4 and 20 h). The dashed line in each graph represents theoretically an E/T of 1:1.
The percentage of killing was calculated using absolute counts of remaining NB4-B7 target cells normalized to non-transduced T cells by flow cytometry (n = 2,
*81.2% transduction efficiency for TCRF5.4, 80.0% for TCR2.5D6, MFI TCRF5.4 = 20818, TCR2.5D6 = 34608). (C,G,H) Non-transduced TCM were used as
negative controls and standard deviations of the mean of triplicates are shown if not otherwise stated. Transduction efficiency and MFI of both TCRs are either
bracketed or referred by an asterisk (*) to the legend. IFN-γ ELISA was performed using supernatants of co-incubations (C,G,H) and multiplexed cytokine analysis by
flow cytometry (F,Gi−iv). (D) Mann–Whitney test: ns: not significant (p > 0.05), (F) Multiple t-test with false discovery rate (FDR) of 1%, ***p < 0.001.
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and IL-2 compared to TCR2.5D6-transduced CD8+ T cells
in experiments with equal TCR transduction rates but again
reduced TCR expression levels. However, these differences
could be compensated by additional MPO2 peptide pulsing
(Figure 1Gi−iv). In contrast, pulsing of three out of four cell lines
with peptide MPO5 did not have a major impact on cytokine
secretion by TCR2.5D6-transgenic T cells. Our data indicate
that HL60, ML2, and NB4 displayed saturating conditions
of endogenously expressed MPO5 eliciting maximal reactivity
of TCR2.5D6 while that was not the case for MPO2 and
TCRF5.4. In case of SiG-M5 with lowest HLA-B7 expression,
cytokine secretion was increased for both MPO-peptides after
additional peptide-pulsing.
In subsequent analyses we investigated the impact of effector
to target ratio titrations (E/T) on IFN-γ release and cytotoxic
capacity of T cells transgenic for both TCR. Again, we observed
differences at high E/T ratios with respect to quantity of IFN-γ
release (Figure 1H, left panels). However, only minor differences
were seen for cytotoxicity of both TCR-transduced T cells after
4 and 20 h of co-incubation (Figure 1H, right panels). At lower
E/T ratios the IFN-γ secretion was comparable for both TCR
and estimated half maximal E/T ratios for IFN-γ secretion as
well as cytotoxicity were slightly favorable for TCRF5.4 at both
time points.
TCR2.5D6 Shows Superior Tumor Control
in vivo Compared to TCRF5.4
Subsequently, we tested both TCRs using the NB4-tumor model
in immune deficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG)
mice (28) to assess whether TCRF5.4 could compete with
TCR2.5D6 in vivo.
For initial in vivo experiments, we used TCR-transgenic
CD8+ TCM and traced the growth of subcutaneous established
tumors in mice that received either TCRF5.4-, TCR2.5D6- or not
transduced T cells. The immunogenicity of the T-cell products
was confirmed by functional in vitro tests prior to intravenous
T-cell injection 8 days after tumor inoculation. The mice were
sacrificed 7 days later for ex vivo analyses. Both TCR show
highly comparable rejection capacity of NB4-B7+ tumors in
comparison to control tumors (Supplementary Figure 2A) also
reflected in significantly reduced tumor weights compared to
the non-transduced T cell group (Supplementary Figure 2B).
The percentage of CD3+ T cells found ex vivo within NB4-
B7+ tumors was similar and significantly enhanced compared
to the non-transduced T-cell group and NB4-B15+ control
tumors (Supplementary Figure 2C). Investigation of T-cell
distribution revealed slightly enhanced presence of TCRF5.4-
T cells in blood and lung compared to TCR2.5D6-T cells
(Supplementary Figure 2D).
To assess the long-term survival of mice, we performed
transfer experiments with T-cell products that were comparable
both in TCR-transduction rate and TCR surface density
expression (Figure 2A). Analyzing T cells from this expanded
transduction before injection confirmed results from previous
experiments with respect to IFNγ secretion and cytotoxicity
independent of the equal TCR transduction rate and expression
level (Figure 2B). Using our in vivo mouse model, we observed
a significant improved tumor control (Figure 2C) and median
survival (Figure 2D) in TCR2.5D6-treated mice (46 days)
compared to TCRF5.4 (28 days). Ex vivo analysis of tumors
discovered a complete loss of HLA-B7eGFP expression of tumor
cells within the TCR2.5D6-group, while the TCRF5.4-group
retained the HLA-B7eGFP expression (Figure 2E). We analyzed
again the T-cell distribution within each mouse (Figure 2F) and
observed only few TCR-transgenic T cells in the BM, blood, lung,
spleen or the tumor of the TCR2.5D6 group. In contrast, in the
TCRF5.4 group, we detected TCR-transgenic T cells in the blood,
lung and the spleen but not within the tumor. These results
demonstrate superior tumor control of TCR2.5D6T cells as well
as different forms of tumor escape in both groups.
Impact of p-MHC Interactions on T-Cell
Recognition by Both TCRs
The discrepancy in tumor control observed for both TCR-
transduced T-cell groups in vivo despite similar functional avidity
and koff-rate was not simply explainable by differences in TCR
expression as this was comparable within the long-term in
vivo experiment. We therefore focused on peptide MHC (p-
MHC) interactions potentially involved in differential function
and investigated peptide affinity and HLA-stability of p-MHC
binding for both MPO peptides in vitro as well as in silico. In
case of the octamer MPO2 we performed additionally pulsing
experiments with the N-terminal (LTPAQLNVL = MPO2+L1)
and C-terminal (TPAQLNVLS = MPO2+S9) prolonged variant
and detected IFN-γ secretion by TCRF5.4-transduced T cells
in response to MPO2+L1 but not for MPO2+S9 (Figure 3A).
Binding predictions of the MPO peptides were applied for
either sequence-based (19, 22, 62) or stability-based predictions
(20) (Table 1). In sequence-based binding affinity predictions,
MPO2 was outperformed by MPO5. However, considering HLA-
complex stability prediction theMPO2-MHC complex seemed to
be more stable compared to the MPO5-MHC complex. Affinity
and HLA-stability predictions for MPO2+L1 indicated weak
performance in both cases.
To verify the stability results of all three MPO-peptides
experimentally, we performed HLA-B7 UV-peptide exchange
assays with titrated amounts of peptide added to a constant
concentration of HLA-B7 monomers bound to a UV-sensitive
peptide. Our data showed that MPO5 is superior to MPO2
with almost one log increased potential to rescue the HLA-
B7 molecule (Figures 3B,C; Table 1) while MPO2+L1 had
the lowest potential for HLA-stabilization. Thus, our results
oppose the results of the NetMHC stability prediction. As
a second experiment, we performed thermal shift assays for
the MPO peptides to characterize their potential to prevent
denaturation of the HLA-complex with ascending temperature
(Supplementary Figure 3A; Table 1). Interestingly the MPO2-
and MPO5-HLA complex heat-associated denaturation is very
similar, as the half maximal melting temperature (V50) for
both peptides, calculated by Boltzmann fitting, was almost
identical (46◦C). The MPO2+L1 complex is more sensitive
to heating (44◦C) while the pp65(417−426) peptide, taken as a
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FIGURE 2 | TCR2.5D6-transduced T cells show superior in vivo tumor killing efficacy. (A) FACS analysis of transduction efficacy for TCRF5.4- and
TCR2.5D6-transduced T cells used for the long-term mouse experiment. The plots show pre-gated living CD3+ cells. X-axis represents the CD8 marker and Y-axis
represents the TCRm+ T-cells. (B) Functionality of TCR-transduced T cells used for the long-term survival experiment of mice shown in (C) measured by IFN-γ release
(right) and cytotoxicity (left) after co-cultivation for 24 h with NB4-B7 tumor cells in an E/T ratio of 1:1 in vitro. (C) Growth kinetic of NB4-B7eGFP tumors in NSG mice
for a period of 58 days. Each line represents an individual tumor growth curve per mouse: n.t (n = 7), TCRF5.4 (n = 7), TCR2.5D6 (n = 7). (D) Kaplan Meier curve of
mice shown in (C), ***p ≤ 0.0002. (E) Percentage of GFP+/HLA-B7+/NB4-B7eGFP tumors cell analyzed ex vivo by flow cytometry at individual time points after
decease of mice shown in (C). Non-transduced (n = 7), TCRF5.4-transduced (n = 7) or TCR2.5D6-transduced T cells (n = 7), nsp ≥ 0.05, ***p = 0.0006. (F)
Percentage of CD3+/TCRm+ living cells in BM, blood, lung, spleen, and tumor analyzed ex vivo by flow cytometry at individual time points after T-cell injection after
decease of mice shown in (C). n.t (n = 7), TCRF5.4-transduced (n = 7) or TCR2.5D6-transduced T cells (n = 7). (C) Transduction efficiency and MFI of both TCRs are
bracketed. (E) Significances are calculated by Mann-Whitney Test. (D) Survival statistics are calculated by Log-rank (Mantel-Cox) test.
FIGURE 3 | MPO5-HLA-B7 complex is superior in comparison to MPO2-HLA-B7 with respect to stability and binding quality. (A) IFN-γ release by TCRF5.4 together
PBMC in response to HLA-B7+ LCL1 cell line pulsed with MPO2 or the non-americ counter partners LTPAQLNVL (MPO2+L1) or TPAQLNVLS (MPO2+S9),
respectively. An E/T ratio of 1:1 was used. IFN-γ secretion of the supernatants after co-cultivation was measured by IFN-γ ELISA. Standard deviations of the mean of
triplicates are shown (n = 2). (B) Beta-2-microglobulin (B2M)-ELISA of UV-mediated peptide exchanged HLA-B7 monomers. V50 values of a Boltzmann fitting for
each MPO-peptide was determined by the optical density of B2M after degraded amounts of MPO-peptides were used for HLA-stabilization. Standard deviations of
the mean of triplicates are shown (n = 3). (C) Pooled results of (B) for MPO5 (n = 4), MPO2 (n = 4), and MPO2+L1 (n = 3). Significance is calculated by
Mann-Whitney Test: *p = 0.0286.
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control, with the highest predicted peptide affinity also has the
highest temperature stability (50◦C). However, the decay of
the MPO HLA-complexes over time at constant 37◦C revealed,
similar to our UV-exchange and in silico sequence-based affinity
prediction results, that MPO5 had a better stabilizing effect
on the MHC complex (4.1 h) compared to MPO2 (3.5 h;
Supplementary Figure 3B; Table 1). In contrast to stability
predictions, we clearly see differences in peptide and HLA-
complex dissociation at physiological temperature indicating that
MPO5 has a longer koff-rate compared to MPO2.
To investigate whether the peptides are differentially
presented on the surface of various target cell lines, we analyzed
the surface presentation of both peptides directly on a panel
of AML cell lines. We used a targeted MS approach using
heavy labeled counterparts of the MPO-peptides as a reference
within each sample. In fact, we observed large differences in the
detection of bothMPOpeptides suggestingMPO2 to bemarkedly
lower presented on the surface of all AML cells lines compared
to MPO5 (Supplementary Figure 3C). In addition, there was a
similar relative intensity of surface peptide presentation between
the different cell lines with SiG-M5 showing the lowest peptide
presentation corresponding to the lowest HLA-B7 density
and recognition by both TCRs (Supplementary Figure 3C;
Figure 1E). However, technical issues need to be considered
as MPO2 may not be efficiently ionized based on its amino
acid sequence. In contrast, the amino acid sequence of MPO5,
especially the arginines at positions 3 and 8, favor the detection
by MS. Thus, comparison of quantitative presentation of both
peptides by MS may have limitations.
Modeling of MPO-Peptide HLA Ligands
Confirms Stable HLA Peptide Binding and
Reduced Fluctuation of MPO5 Within the
Binding Cleft Correlating With
Reduced Cross-Reactivity
For detailed analyses of MPO2/5-HLA-B7 binding properties,
we generated structural models of the complexes and performed
molecular dynamics (MD) simulations for a total time of 450
ns for each system. Figures 4A,B depict a representative MD
conformation of MPO2/5-HLA-B7 complexes and Table 2
presents an alignment of both peptides according to structurally
equivalent residue positions. Our results show that MPO2
features no structurally equivalent residue for W4 in MPO5
and that the TCR accessible residues are Q4, N6, V7 in MPO2,
and W4, D5, E7, R8 in MPO5, respectively (Figures 4A,B;
Table 2; violet residues). Hence, these residues are prone to
affect TCR binding. Figures 4C,D highlight the steric and
electrostatic properties of these solvent-exposed residues.
All other MPO2/5 residues are oriented toward the HLA-B7
peptide binding cleft (Figures 4A,B; Table 2; orange residues).
Of note, strong differences could be observed by analyzing
the conformational stability of both peptides in the bound
complex. MPO5 forms a stable complex structure throughout
all MD simulations. MPO2, however, shows an overall stronger
conformational flexibility, especially toward the N-terminus
(Figures 4E,F), indicating a less stable binding to HLA-B7. This
fits with our Molecular Mechanics/Generalized Born Surface
Area (MM/GBSA)-based binding affinity estimations in which
the affinity of MPO5 is stronger for HLA-B7 compared to MPO2
(1GMPO5MMGBSA: −112.67 kcal mol
−1 with σ = 20.55 and σx¯ =
0.35, 1GMPO2MMGBSA: −88.02 kcal mol
−1 with σ = 9.52 and σx¯ =
0.16, σ: standard deviation, σx¯: standard error of the mean).
The superior binding of MPO5 can be explained by stronger
enthalpic stabilization of the complex as it forms on average
2.25 hydrogen bonds more than MPO2 (Table 3; upper region).
MPO5 is especially stabilized via hydrogen bonds of N1, R3, W4,
and R8 compared to equivalent residues of MPO2 (lower region
of Table 3; Supplementary Table 2). Particularly R3 of MPO5 is
anchored strongly at the bottom of a deep pocket of the HLA-B7
peptide binding cleft via hydrogen bonds of its guanidino group
with HLA-B7 residues S97 and D114 (see Figure 4B; green
inlay). MPO5 shows pronounced flexibility only at position G6
(Figure 4E), which is strongly reduced by Ala- or Thr-exchange
at this position (G6A or G6T; Supplementary Figure 4B,
yellow inlay). This leads to stronger p-MHC binding affinities
(1GG6AMMGBSA: −112.94 kcal mol
−1 with σ = 12.40 and σx¯ =
0.20, 1GG6TMMGBSA: −118.28 kcal mol
−1 with σ = 11.51 and σx¯ =
0.19) as well as to higher IFN-γ release of TCR2.5D6-transduced
T cells (27). In contrast, MPO2 binding is characterized by
high flexibility distributed over several residues (Figure 4E).
This multi-flexibility of the peptide correlates to the reduced
HLA-stability seen in our UV-exchange and thermal shift assays
and the weaker p-MHC binding affinity and constitutes one
conceivable explanation for the reduced surface presentation,
compensable by external peptide pulsing (Figure 1G) as well as
the inferiority of TCRF5.4 in our in vivo experiments. However,
structural features that might explain why MPO2 still binds
well enough, are (i) its residue L5 (Figure 4A, green inlay) as
it sterically fits into the central space of the HLA-B7 peptide
binding cleft, (ii) N6, which forms stable hydrogen bonds with
E152 (Table 3; Supplementary Table 2), and (iii) the central
residues Q4 and L5 are located deeper in the HLA-B7 peptide
binding cleft, leading to a stronger stabilization of these residues
via hydrogen bonds (Table 3; Supplementary Table 2). Further
MD simulations of HLA-B7 complexes comprising Ala/Thr
variants of MPO2/5 supporting the effects described here are
presented in Supplementary Figures 4A,B indicating that also
TCR cross-reactivity may be implicated by peptide binding.
Summarized, our p-MHC modeling strongly promotes our
experimental results and revealed reasons for the weaker MPO2-
HLA-B7 binding quality and in turn why MPO5 is superior in
this regard.
DISCUSSION
We here compared two MHC-mismatched allorestricted TCR
with specificity for two different MPO-derived peptide ligands
presented by HLA-B7 and identified by MS immunopeptidomic
analyses of tumor samples derived from patients with
MPN. Such TCR may be used in the context of allogeneic
stem cell transplantation in a haplo- or sHLAm setting as
well as alternatively within a conditioning regimen using
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FIGURE 4 | MPO2/5-HLA-B7 structure-based modeling revealed less fluctuation of MPO5 within the HLA-binding cleft compared to MPO2. (A,B) Representative
conformation of MPO2/5 in the bound state. The HLA-B7 protein is shown as cartoon representation (gray), the bound peptides are depicted in stick representation
and are highlighted: (hydrogen atoms: white, nitrogen atoms: blue, oxygen atoms: red, carbon atoms: orange or violet), solvent-exposed peptide residues (violet
carbon atoms), peptide residues accommodated by the MHC peptide binding cleft (orange carbon atoms). In the green inlays, the HLA-B7 residues S97 and D114
(blue sticks) are shown for a direct comparison of major differences in the MPO2/5 HLA-B7 binding modes and anchoring to the HLA-B7 peptide binding cleft. Peptide
backbones are shown in orange cartoon representation. (A) The green inlay depicts the MPO2 residues A3 and L5, accommodated by the MHC peptide binding cleft.
(Continued)
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FIGURE 4 | (B) The green inlay depicts the MPO5 residue R3. Hydrogen bonds are highlighted in magenta. (C,D) Space filling models showing the TCR interface of
the MPO2/5-HLA-B7 complexes. Protein is depicted in gray and the bound peptides are depicted as van der Waals (vdW) surface colored according to their
electrostatic potential (white: neutral areas, red: negatively charged areas, blue: positively charged areas). Solvent-exposed and TCRF5.4- or TCR2.5D6-accessible
residues of the MPO2/5-HLA-B7 complexes are highlighted with yellow circles, respectively. (E) Calculated root mean square fluctuations (RMSF) of Cα atoms of the
HLA-B7-bound MPO2/5 peptides (red) and G6A (green)/G6T (blue) variants of MPO5 (average of three independent MD simulations). The individual TCR-recognition
motif from the alanine- and threonine- (Ala/Thr)-scans is shown together with the IFN-γ release (transparent yellow bars) observed in the Ala- or Thr-scan
(Supplementary Figures 1J,K) relative to individual wildtype IFN-γ secretion (empty bars) below the RMSF plots. The height of the empty bars reflects the maximal
IFN-γ release elicited by the wildtype peptide, ↑ = interchangeable amino acid residues. The Ala/Thr-scan for MPO5 is described elsewhere (27). (F) Root mean
square deviation (RMSD) of HLA-B7 protein backbone heavy atoms and MPO2/5 heavy atoms during MD simulations calculated with respect to the initial energy
minimized peptide-HLA-B7 complex models.
TABLE 2 | Alignment of the MPO2 octamer and the MPO5 nonamer peptides according to their HLA-B7-bound structures.
MPO2 P1 P2 P3 P4 P5 P6 P7 P8
T P A Q L N V L
MPO5 P1 P2 P3 P4 P5 P6 P7 P8 P9
N P R W D G E R L
Residues accommodated by the HLA-B7 peptide binding cleft are highlighted in orange. Residues with side chains oriented toward the solvent and thus accessible to T cell receptors
(TCRs) are highlighted in purple. Residue positions are separately named for both peptides in consecutive order. As position P6 of MPO5 and P5 of MPO2 structurally bind into the
same sub-pocket of the HLA-B7 peptide binding cleft they are considered equivalent.
TCR-transgenic T cells. A novel allorestricted TCR (TCRF5.4)
demonstrating high specificity for a new HLA-B7-restricted
MPO2-derived peptide was compared by in-depth functional
characterization with the previously identified TCR2.5D6
(27) in order to define characteristics essential for effective
tumor rejection. In fact, both TCRs differed strongly in their
tumor rejection capacity in our long-term in vivo experiments
using transduced T cells with comparable TCR expression
demonstrating TCR2.5D6 to be clearly superior to TCRF5.4.
The group receiving TCRF5.4-transgenic T cells was not
able to completely reject the tumor and experienced an early
relapse. In contrast, tumor eradication was more effective in
the group of TCR2.5D6, although also these animals relapsed.
However, tumor escape mechanisms were different in both
groups. Whereas, tumors in mice treated with TCR2.5D6-
transduced T cells lacked HLA-B7 and lost all TCR-transgenic
T cells, TCRF5.4-transgenic T cells could be detected in all
examined tissues except in tumors with preserved HLA-
B7 expression. Loss of HLA-B7 indicates the immunogenic
pressure induced by TCR2.5D6-transduced T cells. In contrast,
although TCRF5.4-transgenic T cells have well engrafted, our
experiments indicate that tumor escape relies more on peptide
and/or TCR-intrinsic qualities resulting in T-cell exclusion
from the tumor.
As in vivo experiments are highly laborious, it is desirable to
define in vitro assays most effective in predicting in vivo activity.
Numerous in vitro assays have been proposed to reflect strength
of T-cell response correlating with tumor rejection capacity in
vivo (8–10, 12, 17, 18, 63) although these analyses have been
mainly tested in the autologous setting. In fact, many of these
TCR-dependent functional assays showed comparable results for
both TCR in our experiments and therefore failed to predict in
vivo outcome in the allorestricted setting.
Focusing on differences between our allorestricted TCRs we
observed in almost all TCR transductions reduced quantitative
and qualitative surface expression for TCRF5.4. Although the
quality of TCR expression is critical for T cell performances
and endogenous TCR chains can influence the function and
presentation of transgenic TCR (16), the TCRF5.4 represents
a generally well-expressed TCR. Furthermore, for the detailed
comparisons of both TCRs we used freshly isolated T cell
subpopulations from different healthy donors for several
reasons. (i) First, this minimize donor-dependent effects of
TCR-transgenic T cells that would rule out general statements
for the observed functional qualities. (ii) Second, the use of
freshly isolated donor T cells ensures optimal T-cell fitness
and reduces the impact of T-cell exhaustion because of freeze
and thaw cycles, strenuous selection processes, and/or too long
culture periods. (iii) Third, large numbers of TCR-transductions
using different donor T cells give the opportunity to estimate
possible donor-related heterogeneity in results or, as observed
in our case, a reliable robustness and consistency of T cells
transduced by TCRF5.4 and TCR2.5D6. Furthermore, TCR-
transgenic T cells and HLA-transgenic tumor cell lines were
used without additional adjustment of TCR- or antigen quality
after transduction. Hence, our results include individual
characteristics of both TCRs that would also be present in clinical
settings in the T-cell products for adoptive transfers. However,
for our significant long-term in vivo experiments we selected
T-cell products for both TCR with comparable quantitative and
qualitative TCR expression and still observed inferior tumor
rejection capacity of TCRF5.4-transduced T cells. These results
indicate that differences in TCR expression may not represent
a decisive criterion for TCR selection in our case. Especially, we
could not confirm any correlation of in vivo anti-tumor reactivity
to dissociation half-lives of TCRs from their p-MHC complexes
(12, 64) as well as functional avidity of TCRs toward the cognate
MHC-peptide complexes (9). This could be explained by specific
features of MHC-mismatched TCRs as they have alternative
binding properties to the mismatched MHC (65) compensating
for lower affinity of the peptide toward MHC as well as the TCR
toward peptide.
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TABLE 3 | Comparison of the average number of peptide-HLA-B7 binding cleft hydrogen bonds observed during the MD simulations for the bound MPO2/5 peptides.
MPO2-HLA-B*07:02 MPO5-HLA-B*07:02 <hb>MPO2-<hb>MPO5
Entire peptide <hb>a Entire peptide <hb>
SCb 1.13 SC 4.36 −3.23
BBc 7.51 BB 6.53 0.98
SC+BB 8.64 SC+BB 10.89 −2.25
Individual peptide residues Individual peptide residues
P1 P1
T1SC 0.43 N1SC 1.14 −0.71
T1BB 1.26 N1BB 1.78 −0.52
T1SC+BB 1.69 N1SC+BB 2.92 −1.23
P3 P3
A3SC 0.00 R3SC 2.01 −2.01
A3BB 0.66 R3BB 0.39 0.27
A3SC+BB 0.66 R3SC+BB 2.40 −1.74
Missing residue P4
/ 0.00 W4SC 0.46 −0.46
P4 P5
Q4SC 0.17 D5SC 0.23 −0.06
Q4BB 0.25 D5BB 0.04 0.21
Q4SC+BB 0.42 D5SC+BB 0.27 0.15
P5 P6
L5BB 0.27 G6BB 0.11 0.16
P6 P7
N6SC 0.53 E7SC 0.00 0.53
N6BB 0.22 E7BB 0.15 0.07
N6SC+BB 0.75 E7SC+BB 0.15 0.60
P7 P8
V7SC 0.00 R8SC 0.52 −0.52
V7BB 0.61 R8BB 0.67 −0.06
V7SC+BB 0.61 R8SC+BB 1.19 −0.58
P8 P9
L8BB 4.24 L9BB 3.39 0.85
The upper part of the table compares the overall average number of hydrogen bonds for both peptides. The average number of hydrogen bonds are further subdivided in peptide side
chain (SC)-mediated and peptide backbone (BB)-mediated hydrogen bonds. The lower part of the table compares the average number of hydrogen bonds for structurally equivalent
residue positions in both peptides. Red: the MPO2 peptide forms less hydrogen bonds at a specific residue position compared to the MPO5 peptide, green: the MPO2 peptide forms
more hydrogen bonds at a specific residue position compared to the MPO5 peptide. Only peptide residues that form SC- or BB-mediated hydrogen bonds with the HLA-B7 protein for
at least one of the two peptides are listed and in these cases SC- or BB-mediated hydrogen bonds are always listed for both peptides.
aAverage number of hydrogen bonds per molecular dynamics time frame; bSC, only side chain hydrogen bond interactions of the corresponding peptide or residue are considered;
cBB, only backbone hydrogen bond interactions of the corresponding peptide or residue are considered.
Differences in quantitative and qualitative cytokine secretion,
however, revealed to be the most significant indicator for reduced
in vivo performance seen in almost all in vitro analyses with
differing but also equal TCR expression potentially explaining
inferiority in tumor rejection (66, 67). In contrast, TCRF5.4-
transduced T cells were competitive to those transduced with
TCR2.5D6 with respect to in vitro cytotoxicity being in line
with previous observations that this functional quality may
not represent the most sensitive test for T-cell responses even
with differing TCR expression rates (68) indicating once more
that TCR expression is not the most indicative factor for
TCR functionality.
In contrast, our data support that peptide presentation on
the surface of tumor cells may represent a key factor for
effective tumor rejection. In fact, although the MPO antigen
expression in this work was every time identically for both
TCR conditions as the targeted tumor cell lines were the
same, the MPO-derived target peptide presentation for MPO2
and MPO5 was obviously different. Our results indicate a
reduced peptide binding of MPO2 to HLA-B7 when comparing
both peptides by either UV exchange assays, thermal shift
assays or predicted HLA-affinity suggesting that reduced peptide
binding toward HLA-B7 plays a major role in inferior tumor
rejection. Although the absolute quantification of peptides on
the surface of target cells by MS harbors major limitations, our
MS data may support an inferior MHC presentation of MPO2
compared to MPO5 due to its highly reduced detection. Our
data thereby confirm data from Engels et al. highlighting the
role of peptide binding to tumor rejection (18), here in an
MHC-mismatched setting.
To further deepen our understanding of p-MHC binding, we
applied structure-based modeling and atomistic MD simulations
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and realized the potential of molecular modeling and simulation
to rationalize the results of our peptide stability and amino
acid substitution assays on a molecular level. We thereby not
only confirmed UV exchange assays as well as sequence-based
affinity prediction but also discovered MPO5 to be more rigid
within the peptide binding cleft due to better stabilization of
amino acid residues by hydrogen bonds at individual positions
in comparison to MPO2. This finding, in fact, may be decisive for
a high specificity of a selected TCR as more flexible amino acid
residue positions of the peptide may impede stable binding of
the TCR to peptide MHC. Indeed, we can explain by Cα atoms
fluctuations especially for the MPO5 peptide that the binding
quality of respective amino acid residues in their HLA-binding
pocket favors a more stable peptide binding. The high flexibility
in position 6 is markedly reduced after exchange by alanine or
threonine indicating stabilization of the peptide toward HLA-
B7. Importantly, reactivity of the TCR does not depend on
the glycine within the wildtype peptide and is even enhanced
after stabilization of the peptide by alanine or threonine. In
contrast, the enhanced fluctuation observed for several amino
acid residues of the MPO2 peptide correlates with overall
less formed hydrogen bonds between the p-MHC complex
FIGURE 5 | Workflow for identification of allo-MHC-restricted tumor-reactive TCRs. Proposed workflow for TCR identification: (1) Immunopeptidomics of patient
samples and tumor material; (2) Evaluation of antigen expression on human tissues; (3,4) in silico prediction of candidate peptides for first ranking and experimental
validation by HLA-affinity and/or HLA-stability assays in combination with p-MHC modeling; (5,6) TCR identification and TCR isolation; (7) TCR characterization with
special interest to TCR surface presentation, cytokine secretion and specificity; (8) Characterization of the safety profile of TCR-transgenic T cells using LCL cell lines,
amino acid substitution experiments and screening of homologous peptides in combination with structure-based modeling approaches. Critical assays for the
identification of suitable TCR and peptides used in our analyses are highlighted in bold characters.
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compared to MPO5 and more flexibility of p-MHC recognition
within the alanine and threonine scan. Taken together, our data
extend previous publications (69) and indicate, that for cross-
reactivity testing at least two different amino acids for amino
acid substitution assays are necessary to assess possible TCR-
binding motifs.
Moreover, there seems to be a correlation between the
described flexibility of p-MHC binding as analyzed by structure-
based modeling and the cross-reactivity of TCRF5.4 as identified
by its observed flexibility to amino acids exchanges of
the peptide, the high number of peptides predicted to be
recognized by TCRF5.4 by ScanProsite as well as its MHC-
cross-reactivity toward HLA-B51 which is in contrast to the
observations made for TCR2.5D6. In this regard the rigidness
evaluation of peptide-HLA binding might have the potential
to serve as an appropriate tool to predict cross-reactivity.
Although structure-based modeling of p-MHC complexes can
provide valuable insights into the molecular basis of TCR-p-
MHC recognition, this strongly depends on the availability of
experimental structural data of p-MHC either of the HLA to
be investigated or of close homologs. As the latter is often the
case for many MHC proteins, homology modeling approaches
can nowadays be applied to construct MHC protein models
for most HLA-alleles. Bound peptides can be modeled via
side chain placement/mutation algorithms using MHC-bound
peptide backbone coordinates from X-ray structures as template.
As peptide binding is determined by the structural and chemical
characteristics of the binding cleft of the specific MHC allele,
binding features have to be analyzed on an allele-specific basis.
For this, standard analysis approaches, which are readily available
for most MD-simulation packages, can be applied, such as
hydrogen bond analysis (for, e.g., hydrophilic binding pockets)
or residue contact maps (for, e.g., hydrophobic binding pockets)
or combinations thereof.
Although the number of TCRs studied here is limited and
more TCR candidates need to be tested to further prove our
conclusions, our integrated view in TCR functionality and p-
MHC binding suggests the quality and quantity of cytokine
release and the characteristics of p-MHC binding as most
relevant factors to be analyzed for a fast and efficient TCR
identification procedure in the allogeneic MHC-mismatched
repertoire. We conclude that an interdisciplinary approach
between in silico-, T-cell-, and structural analyses is most
promising to address the challenges of identification of TCR
with high efficacy and safety profiles. We propose a curtailed
procedure to identify allorestricted TCRs presumably also
applicable to be used for other settings as for autologous TCR
specific for other tumor-associated antigens and neoantigens
(Figure 5). The final aim of this workflow is to identify efficiently
TCR candidates for clinical translation to enable personalized
immunotherapies with high tumor reactivity and a favorable
safety profile.
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